These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32790040)

  • 1. Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab.
    Garcia-Melendo C; Vilarrasa E; Cubiró X; Bittencourt F; Puig L
    Dermatol Ther; 2020 Nov; 33(6):e14180. PubMed ID: 32790040
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to 'Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on "Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab"'.
    López Sanz P; Guzmán Pérez M; Guerrero Ramírez C; Manso Córdoba S; Alfaro Martínez ME; Azaña Defez JM
    Clin Exp Dermatol; 2023 Jul; 48(8):940-941. PubMed ID: 37098182
    [No Abstract]   [Full Text] [Related]  

  • 3. Secukinumab-induced paradoxical hidradenitis suppurativa successfully treated with adalimumab.
    Babino G; D'Ambra I; Fulgione E; Alfano R; Verolino P; Argenziano G
    Int J Dermatol; 2022 Feb; 61(2):e79-e80. PubMed ID: 34258759
    [No Abstract]   [Full Text] [Related]  

  • 4. Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.
    Burzi L; Repetto F; Ribero S; Mastorino L; Quaglino P; Dapavo P
    Dermatol Ther; 2022 Dec; 35(12):e15866. PubMed ID: 36175129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on 'Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab'.
    Martora F; Fabbrocini G; Marasca C; Battista T; Megna M
    Clin Exp Dermatol; 2023 Jun; 48(6):701-703. PubMed ID: 36883596
    [No Abstract]   [Full Text] [Related]  

  • 6. Paradoxical Reaction in a Patient with Hidradenitis Suppurativa Undergoing Adalimumab Treatment.
    Ikeya S; Takeichi T; Taki T; Muro Y; Ogi T; Akiyama M
    Acta Derm Venereol; 2021 Jun; 101(6):adv00484. PubMed ID: 34043022
    [No Abstract]   [Full Text] [Related]  

  • 7. Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience.
    Koszegi B; Wilson A; Stone C; Satgé F; Cowan TL; Murrell DF
    Clin Exp Dermatol; 2023 Oct; 48(11):1266-1269. PubMed ID: 37434310
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V; Mrowietz U
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New onset vitiligo in a patient with hidradenitis suppurativa treated with adalimumab.
    Phan K; Charlton O; Smith SD
    Dermatol Ther; 2020 May; 33(3):e13347. PubMed ID: 32239739
    [No Abstract]   [Full Text] [Related]  

  • 10. Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa.
    Vignoli CA; Gargiulo L; Sanna F; Narcisi A; Costanzo A
    J Dermatolog Treat; 2023 Dec; 34(1):2256905. PubMed ID: 37705359
    [No Abstract]   [Full Text] [Related]  

  • 11. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
    Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
    J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa.
    Ricceri F; Rosi E; Di Cesare A; Pescitelli L; Fastame MT; Prignano F
    Dermatol Ther; 2020 Nov; 33(6):e14387. PubMed ID: 33030281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
    Berman HS; Villa NM; Shi VY; Hsiao JL
    J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS.
    Shaharir SS; Jamil A; Chua SH; Arumugam M; Rosli N
    Dermatol Ther; 2020 Nov; 33(6):e14021. PubMed ID: 32677247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role?
    Burzi L; Repetto F; Ramondetta A; Rozzo G; Licciardello M; Ribero S; Quaglino P; Dapavo P
    Dermatol Ther; 2021 May; 34(3):e14930. PubMed ID: 33665949
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review.
    Montero-Vilchez T; Martinez-Lopez A; Salvador-Rodriguez L; Arias-Santiago S; Molina-Leyva A
    Dermatol Ther; 2020 May; 33(3):e13456. PubMed ID: 32319172
    [No Abstract]   [Full Text] [Related]  

  • 17. Paradoxical hidradenitis suppurativa to biologic agents: a case series and literature review.
    Neves JM; Cunha N; Lencastre A; Cabete J
    Int J Dermatol; 2019 Nov; 58(11):e226-e228. PubMed ID: 31290151
    [No Abstract]   [Full Text] [Related]  

  • 18. Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: A retrospective bicentric experience.
    Melgosa Ramos FJ; García Ruiz R; Mateu Puchades A; Alfageme Roldán F
    Dermatol Ther; 2022 Jul; 35(7):e15558. PubMed ID: 35510581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab.
    Moul DK; Korman NJ
    Arch Dermatol; 2006 Sep; 142(9):1110-2. PubMed ID: 16982997
    [No Abstract]   [Full Text] [Related]  

  • 20. Two paradoxical reactions in a patient with psoriasis and psoriatic arthritis: Adalimumab-induced hidradenitis suppurativa and secukinumab-induced alopecia areata.
    Öğüt ND
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):e468-e469. PubMed ID: 36151938
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.